Frontiers in Cardiovascular Medicine (Nov 2022)

Cardiac magnetic resonance follow-up of COVID-19 vaccine associated acute myocarditis

  • Dmitrij Kravchenko,
  • Dmitrij Kravchenko,
  • Alexander Isaak,
  • Alexander Isaak,
  • Narine Mesropyan,
  • Narine Mesropyan,
  • Leon M. Bischoff,
  • Leon M. Bischoff,
  • Claus C. Pieper,
  • Ulrike Attenberger,
  • Daniel Kuetting,
  • Daniel Kuetting,
  • Sebastian Zimmer,
  • Sebastian Zimmer,
  • Christopher Hart,
  • Christopher Hart,
  • Julian A. Luetkens,
  • Julian A. Luetkens

DOI
https://doi.org/10.3389/fcvm.2022.1049256
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundMass COVID-19 vaccination campaigns have helped impede the COVID-19 pandemic. In rare cases, some vaccines have led to vaccine associated myocarditis in a specific subset of the population, usually young males. Cardiac magnetic resonance (CMR) can reliably diagnose vaccine associated myocarditis, but follow-up data of CMR proven acute myocarditis is scarce.Materials and methodsNine patients with acute vaccine associated myocarditis underwent baseline and follow-up CMR examinations and were compared to baseline parameters at initial presentation and to a group of 20 healthy controls. CMR protocol included functional assessment, T1 and T2 mapping, T2 signal intensity ratio, strain feature tracking, and late gadolinium enhancement (LGE).ResultsMyocarditis patients (n = 9, aged 24 ± 6 years, 8 males) underwent CMR follow-up after an average of 5.8 ± 4.3 months. All patients showed a complete resolution of visual myocardial edema while also demonstrating a reduction in overall LGE extent from baseline to follow-up (4.2 ± 2.1 vs. 0.9 ± 0.8%, p < 0.001), although visual LGE was still noted in all patients. Left ventricular ejection fraction was normal at baseline and at follow-up (58 ± 6 vs. 62 ± 4%, p = 0.10) as well as compared to a healthy control group (60 ± 4%, p = 0.24). T1 (1024 ± 77 vs. 971 ± 34 ms, p = 0.05) and T2 relaxations times (57 ± 6 vs. 51 ± 3 ms, p = 0.03) normalized at follow-up. Most patients reported a resolution of clinical symptoms, while two (22%) reported new onset of exertional dyspnea.ConclusionPatients with COVID-19 vaccine associated acute myocarditis showed a complete, uncomplicated resolution of myocardial inflammation on follow-up CMR, which was associated with a near complete resolution of symptoms. Minor, residual myocardial scarring was present on follow-up LGE imaging. The long-term implications of the remaining myocardial scar-tissue after vaccine associated myocarditis remain unknown warranting further studies.

Keywords